"Look we’re deliberately doing it low to leave a lot of upside...

"Look we’re deliberately doing it low to leave a lot of upside on the table, I think we’ll get traction pretty quickly and you’ll see us start to come up near the other stem cell companies. Stem cell companies that are in the clinic or even pre-clinical, are in the hundreds of millions; of course Mesoblast (ASX:MSB) is $1.8 billion market cap. So we’ve got some good upside in terms of where we’re going."

This is going to a few dollars a share as Cynata!!! Talk about low hanging fruit!

http://www.ecoquest.com.au/news-media/